As part of the Canadian Strategy for Personalized Management of Pancreatic Cancer [Casper-PANC], the three participating Canadian PRECEDE Sites [the University Health Network/Ontario Institute for Cancer Research, the McGill University Health Centre, and the British Columbia Cancer Research Institute] among other Canadian cancer research centers, have received $7.5M over 5 years [Jan 2023 to Dec 2027] from the Canadian Cancer Society to address unmet clinical needs in pancreatic cancer care, with $1.2M directed towards early detection studies. Casper-PANC is leading the Canadian contribution to the ongoing international PRECEDE Consortium.